NCT05740423

Brief Summary

The proper period of anti-seizure medication (ASM) treamtment is important for decreasing side effect of ASM and recurrence of seizure. We evaluate reliable risk factor analysis for safe withdrawal of ASM in children with epilepsy. Futhermore, we develop the scoring system for prediction of seizure recurrence to set the standard for safe withdrawal of ASM.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 30, 2021

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

January 3, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 23, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

February 23, 2023

Status Verified

February 1, 2023

Enrollment Period

3.3 years

First QC Date

January 3, 2023

Last Update Submit

February 13, 2023

Conditions

EpilepsyEpilepsy in Children

Outcome Measures

Primary Outcomes (1)

  • Patients umber of seizure recurrence

    Patients umber of seizure recurrence

    Up to 2 years

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients with Epilepsy or acute provoked seizure according to the ILAE guideline

You may qualify if:

  • Patients with Epilepsy or acute provoked seizure according to the ILAE guideline
  • Patients with 2 years of seizure free periods

You may not qualify if:

  • Uncertain diagnosis of epilepsy or acute provoked seizure
  • Patients who do not want to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asan Medical Center

Seoul, 05505, South Korea

RECRUITING

MeSH Terms

Conditions

Epilepsy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Min-Sun Yum

    Asan Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Min-Jee Kim

CONTACT

821045204711pradoxwh@naver.com

Min-Sun Yum

CONTACT

+82230103386misun.yum@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
24 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 3, 2023

First Posted

February 23, 2023

Study Start

August 30, 2021

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

February 23, 2023

Record last verified: 2023-02

Locations

KR(1)